General contact

Head Office
Novartis International AG
CH-4002 Basel
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)

Investors

Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland

+41 61 324 79 44

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

pane 4 content

Ongoing R&D

A joint research program is ongoing at the Novartis Institute for Tropical Diseases, Genomics Institute of the Novartis Research Foundation, Swiss Tropical and Public Health Institute and Scripps Research Institute to discover the next generation of antimalarial drugs.

The program is funded by the Welcome Trust, the Development Board of Singapore and the Medicines for Malaria Venture (MMV).

Novartis Institute for Tropical Diseases

The Novartis Institute for Tropical Diseases (NITD) is dedicated to researching novel treatments for major tropical diseases including malaria.

  1. Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, De Palacios PI. Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 2005; 99(6):459-467.
  2. van Vugt M, Wilairatana P, Gemperli B, Gathmann I, Phaipun L, Brockman A et al. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg 1999; 60(6):936-942.
  3. Meister S, Plouffe DM, Kuhen KL, Bonamy GM, Wu T, Barnes SW et al. Imaging of Plasmodium liver stages to drive next generation antimalarial drug discovery. Science 2011;334:1372–7.)